Treatment with a fully human anti-cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) antibody has been associated with long-lasting responses in several hematologic malignancies [51] and a high proportion of durable, complete responses in patients with advanced metastatic melanoma [52]. The gene discussed is CTLA4; the disease is hematologic disorder.